首页 > 最新文献

Current gene therapy最新文献

英文 中文
Acetylresveratrol (AC-Res): An Evolving Frontier in Modulating Gene Expression. 乙酰白藜芦醇(AC-Res):调节基因表达的前沿技术。
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-06-10 DOI: 10.2174/0115665232291487240603093218
Uttam Prasad Panigrahy, Rahul Subhash Buchade, Sandhya S, Anoop Kumar N, Sachinkumar Dnyaneshwar Gunjal, E Selvakumari, Narendra Kumar Pandey, Ankita Wal

Background: Acetylresveratrol (AC-Res), to date, is a powerful stilbene phytoalexin generated organically or as a component of a plant's defensive system, is a significant plant phenolic chemical portion and is investigated as a therapy option for a number of disorders. Owing to its inadequate stabilisation and considerable conformation rigidity, the utility of AC-Res as a medication is limited.

Objective: The current review article outlined the structure of AC-Res, their methods of activity, and the latest technological progress in the administration of these molecules. It is conceivable to deduce that AC-Res has a variety of consequences for the cellular functions of infected cells.

Methods: The literature survey for the present article was gathered from the authentic data published by various peer-reviewed publishers employing Google Scholar and PubMedprioritizing Scopus and Web of Science indexed journals as the search platform focusing on AC-Res pharmacological actions, particularly in the English language.

Result: Despite its extensive spectrum of biological and therapeutic applications, AC-Res has become a source of increasing concern. Depending on the researchers, AC-Res possesses radioprotective, cardioprotective, neurological, anti-inflammatory, and anti-microbial potential. It also has anti-cancer and antioxidant properties.

Conclusion: To avoid non-specific cytotoxicity, optimization efforts are presently emphasizing the possible usage of AC-Res based on nanocrystals, nanoparticles and dendrimers, and nanocrystals. Finally, while using AC-Res in biology is still a way off, researchers agree that if they continue to explore it, AC-Res and similar parts will be recognized as actual possibilities for a variety of things in the next years.

背景:乙酰基白藜芦醇(AC-Res)是一种强效的二苯乙烯类植物毒素,可有机生成或作为植物防御系统的组成部分,是一种重要的植物酚类化学成分,被研究用于治疗多种疾病。由于 AC-Res 不够稳定且构象相当僵化,其作为药物的效用受到了限制:本综述文章概述了 AC-Res 的结构、其活性方法以及这些分子在用药方面的最新技术进展。可以推断,AC-Res 对感染细胞的细胞功能有多种影响:本文的文献调查是通过谷歌学者(Google Scholar)和PubMed优先使用Scopus和Web of Science索引期刊作为搜索平台,从各同行评审出版商发表的真实数据中收集的,重点关注AC-Res的药理作用,尤其是英文文献:结果:尽管 AC-Res 在生物和治疗方面应用广泛,但它已成为一个日益令人担忧的问题。根据研究人员的研究,AC-Res 具有放射保护、心脏保护、神经、抗炎和抗微生物的潜力。它还具有抗癌和抗氧化特性:结论:为了避免非特异性细胞毒性,目前的优化工作重点是在纳米晶体、纳米颗粒和树枝状聚合物以及纳米晶体的基础上使用 AC-Res。最后,虽然 AC-Res 在生物学中的应用还遥遥无期,但研究人员一致认为,如果继续探索,AC-Res 和类似部件将在未来几年内被公认为可以实际应用于各种领域。
{"title":"Acetylresveratrol (AC-Res): An Evolving Frontier in Modulating Gene Expression.","authors":"Uttam Prasad Panigrahy, Rahul Subhash Buchade, Sandhya S, Anoop Kumar N, Sachinkumar Dnyaneshwar Gunjal, E Selvakumari, Narendra Kumar Pandey, Ankita Wal","doi":"10.2174/0115665232291487240603093218","DOIUrl":"https://doi.org/10.2174/0115665232291487240603093218","url":null,"abstract":"<p><strong>Background: </strong>Acetylresveratrol (AC-Res), to date, is a powerful stilbene phytoalexin generated organically or as a component of a plant's defensive system, is a significant plant phenolic chemical portion and is investigated as a therapy option for a number of disorders. Owing to its inadequate stabilisation and considerable conformation rigidity, the utility of AC-Res as a medication is limited.</p><p><strong>Objective: </strong>The current review article outlined the structure of AC-Res, their methods of activity, and the latest technological progress in the administration of these molecules. It is conceivable to deduce that AC-Res has a variety of consequences for the cellular functions of infected cells.</p><p><strong>Methods: </strong>The literature survey for the present article was gathered from the authentic data published by various peer-reviewed publishers employing Google Scholar and PubMedprioritizing Scopus and Web of Science indexed journals as the search platform focusing on AC-Res pharmacological actions, particularly in the English language.</p><p><strong>Result: </strong>Despite its extensive spectrum of biological and therapeutic applications, AC-Res has become a source of increasing concern. Depending on the researchers, AC-Res possesses radioprotective, cardioprotective, neurological, anti-inflammatory, and anti-microbial potential. It also has anti-cancer and antioxidant properties.</p><p><strong>Conclusion: </strong>To avoid non-specific cytotoxicity, optimization efforts are presently emphasizing the possible usage of AC-Res based on nanocrystals, nanoparticles and dendrimers, and nanocrystals. Finally, while using AC-Res in biology is still a way off, researchers agree that if they continue to explore it, AC-Res and similar parts will be recognized as actual possibilities for a variety of things in the next years.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role and Treatment Strategies of Ammonia-Related Metabolism in Tumor Microenvironment. 氨相关代谢在肿瘤微环境中的作用和治疗策略
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-06-10 DOI: 10.2174/0115665232301222240603100840
Qizhen Ye, Dan Li, Yi Zou, Ying Yuan

Tumor cells achieve their adaptability through various metabolic reprogramming processes. Among them, ammonia, as a traditional metabolic waste, plays an increasingly important role in the tumor microenvironment along with its associated metabolites. Other cells in the microenvironment can also reshape the immune status of the microenvironment by regulating ammonia-related metabolism, and targeting this metabolic aspect has emerged as a potential strategy for tumor treatment. In this study, we have systematically reviewed the source and destination of ammonia in tumor cells, as well as the links between ammonia and other biological processes. We have also analyzed the ammonia-related metabolic regulation of other cells (including T cells, macrophages, dendritic cells, natural killer cells, myeloid-derived suppressor cells, and stromal cells) in the tumor microenvironment, and summarized the tumor treatment methods that target this metabolism. Through ammonia-related metabolic reprogramming, tumor cells obtain the energy they need for rapid growth and proliferation. Multiple immune cells and stromal cells in the microenvironment also interact with each other through this metabolic regulation, ultimately leading to immune suppression. Despite the heterogeneity of tumors and the complexity of cellular functions, further research into therapeutic interventions targeting ammonia-related metabolism is warranted. This review has focused on the role and regulation of ammonia-related metabolism in tumor cells and other cells in the microenvironment, and highlighted the efficacy and prospects of targeted ammonia-related metabolism therapy.

肿瘤细胞通过各种代谢重编程过程实现其适应性。其中,氨作为一种传统的代谢废物,与相关代谢产物一起在肿瘤微环境中发挥着越来越重要的作用。微环境中的其他细胞也可通过调节氨相关代谢重塑微环境的免疫状态,针对这一代谢环节的研究已成为治疗肿瘤的潜在策略。在本研究中,我们系统回顾了肿瘤细胞中氨的来源和去向,以及氨与其他生物过程之间的联系。我们还分析了肿瘤微环境中其他细胞(包括 T 细胞、巨噬细胞、树突状细胞、自然杀伤细胞、髓源抑制细胞和基质细胞)与氨相关的代谢调控,并总结了针对这种代谢的肿瘤治疗方法。通过与氨相关的代谢重编程,肿瘤细胞获得了快速生长和增殖所需的能量。微环境中的多种免疫细胞和基质细胞也通过这种代谢调节相互作用,最终导致免疫抑制。尽管肿瘤具有异质性和细胞功能的复杂性,但仍有必要进一步研究针对氨相关代谢的治疗干预措施。本综述重点探讨了氨相关代谢在肿瘤细胞和微环境中其他细胞中的作用和调控,并强调了氨相关代谢靶向治疗的疗效和前景。
{"title":"The Role and Treatment Strategies of Ammonia-Related Metabolism in Tumor Microenvironment.","authors":"Qizhen Ye, Dan Li, Yi Zou, Ying Yuan","doi":"10.2174/0115665232301222240603100840","DOIUrl":"https://doi.org/10.2174/0115665232301222240603100840","url":null,"abstract":"<p><p>Tumor cells achieve their adaptability through various metabolic reprogramming processes. Among them, ammonia, as a traditional metabolic waste, plays an increasingly important role in the tumor microenvironment along with its associated metabolites. Other cells in the microenvironment can also reshape the immune status of the microenvironment by regulating ammonia-related metabolism, and targeting this metabolic aspect has emerged as a potential strategy for tumor treatment. In this study, we have systematically reviewed the source and destination of ammonia in tumor cells, as well as the links between ammonia and other biological processes. We have also analyzed the ammonia-related metabolic regulation of other cells (including T cells, macrophages, dendritic cells, natural killer cells, myeloid-derived suppressor cells, and stromal cells) in the tumor microenvironment, and summarized the tumor treatment methods that target this metabolism. Through ammonia-related metabolic reprogramming, tumor cells obtain the energy they need for rapid growth and proliferation. Multiple immune cells and stromal cells in the microenvironment also interact with each other through this metabolic regulation, ultimately leading to immune suppression. Despite the heterogeneity of tumors and the complexity of cellular functions, further research into therapeutic interventions targeting ammonia-related metabolism is warranted. This review has focused on the role and regulation of ammonia-related metabolism in tumor cells and other cells in the microenvironment, and highlighted the efficacy and prospects of targeted ammonia-related metabolism therapy.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human Virus-Like Proteins: Implications for Gene Therapy. 人类病毒样蛋白:对基因疗法的影响。
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-05-24 DOI: 10.2174/0115665232303436240515071754
Aya Al Othman, Anna Polyanskaya, Mikhail Durymanov

An analysis of mammalian genomes has revealed a significant number of DNA sequences with transposon or viral origin. Some of these elements encode functional proteins, repurposed during evolution to play significant physiological roles in certain tissues. Some human virus-like proteins, such as Peg10 and Arc/Arg3.1, structurally demonstrate significant similarity with Gag retroviral proteins, while others, like syncytins-1 and -2, resemble envelope viral proteins. In recent years, it has become clear that these proteins can be exploited for bioengineering 'humanized' capsid particles aimed at targeted mRNA delivery. Realizing this idea could provide efficient virus-like particles for gene therapy and address the problem of viral vector immunogenicity. This review provides an overview of the most-studied human proteins of viral or transposon origin and highlights their biological functions. Additionally, recent advances in exploiting these proteins for targeted mRNA delivery and prospects for their clinical application are discussed.

通过对哺乳动物基因组的分析,发现了大量源自转座子或病毒的 DNA 序列。其中一些元件编码功能蛋白,在进化过程中被重新利用,在某些组织中发挥重要的生理作用。一些人类病毒样蛋白,如 Peg10 和 Arc/Arg3.1,在结构上与 Gag 逆转录病毒蛋白非常相似,而另一些蛋白,如 syncytins-1 和-2,则类似于包膜病毒蛋白。近年来,这些蛋白显然可用于生物工程 "人性化 "的囊膜颗粒,以定向传递 mRNA。实现这一想法可为基因治疗提供高效的类病毒颗粒,并解决病毒载体的免疫原性问题。本综述概述了研究最多的病毒或转座子来源的人类蛋白质,并重点介绍了它们的生物学功能。此外,还讨论了利用这些蛋白质进行 mRNA 靶向传递的最新进展及其临床应用前景。
{"title":"Human Virus-Like Proteins: Implications for Gene Therapy.","authors":"Aya Al Othman, Anna Polyanskaya, Mikhail Durymanov","doi":"10.2174/0115665232303436240515071754","DOIUrl":"https://doi.org/10.2174/0115665232303436240515071754","url":null,"abstract":"<p><p>An analysis of mammalian genomes has revealed a significant number of DNA sequences with transposon or viral origin. Some of these elements encode functional proteins, repurposed during evolution to play significant physiological roles in certain tissues. Some human virus-like proteins, such as Peg10 and Arc/Arg3.1, structurally demonstrate significant similarity with Gag retroviral proteins, while others, like syncytins-1 and -2, resemble envelope viral proteins. In recent years, it has become clear that these proteins can be exploited for bioengineering 'humanized' capsid particles aimed at targeted mRNA delivery. Realizing this idea could provide efficient virus-like particles for gene therapy and address the problem of viral vector immunogenicity. This review provides an overview of the most-studied human proteins of viral or transposon origin and highlights their biological functions. Additionally, recent advances in exploiting these proteins for targeted mRNA delivery and prospects for their clinical application are discussed.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines 在美国和欧盟开发用于临床的细胞和基因疗法:监管指南摘要
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-04-27 DOI: 10.2174/0115665232306205240419091414
Anand Rotte
Recent decades have seen advancements in the management and treatment of difficult-- to-treat diseases such as cancer. A special class of therapeutics called cell and gene therapy has been introduced in the past 10 years. Cell and gene therapy products have strengthened the treatment options for life-threatening diseases with unmet clinical needs and also provided the possibility of a potential cure for the disease in some of the patients. Cell and gene therapy products are gaining recognition, and the interest in clinical development of cell and gene therapy products is increasing. Moreover, as the class of cell and gene therapy products is relatively new, there is a limited regulatory experience in the development, and the developers of the cell and gene therapy products can often be puzzled with an array of questions on regulations. The current review intends to provide a basic understanding of regulatory guidelines from the FDA and EMA that are applicable to cell and gene therapy products. Essentials such as which office is responsible for the evaluation of applications, which regulatory class/pathway is appropriate for development, and what are the quality, nonclinical and clinical studies that are needed to support the application are discussed in the article. In addition, a summary of regulatory designations and the post-approval requirements, such as Risk Evaluation and Mitigation Strategies (REMS) and long-term follow- up, is included in the article. Developers (referred to as ‘sponsors’ in this article) of cell and gene therapies can use the respective guidance documents and other specific review articles cited in this review for detailed information on the topics.
近几十年来,癌症等难治疾病的管理和治疗取得了长足进步。在过去 10 年中,出现了一类特殊的疗法,即细胞和基因疗法。细胞和基因治疗产品加强了对临床需求未得到满足的危及生命的疾病的治疗选择,也为部分患者提供了治愈疾病的可能性。细胞和基因治疗产品正得到越来越多的认可,人们对细胞和基因治疗产品临床开发的兴趣也在不断增加。此外,由于细胞和基因治疗产品是相对较新的一类产品,在开发过程中的监管经验有限,细胞和基因治疗产品的开发者往往会对监管方面的一系列问题感到困惑。本综述旨在让人们基本了解适用于细胞和基因治疗产品的 FDA 和 EMA 监管指南。文章讨论了一些基本要素,如哪个部门负责评估申请,哪个监管类别/途径适合开发,支持申请所需的质量、非临床和临床研究有哪些。此外,文章还概述了监管指定和批准后的要求,如风险评估与缓解策略(REMS)和长期随访。细胞和基因疗法的开发者(本文中称为 "申办者")可参阅本综述中引用的相关指导文件和其他特定综述文章,了解有关主题的详细信息。
{"title":"Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory Guidelines","authors":"Anand Rotte","doi":"10.2174/0115665232306205240419091414","DOIUrl":"https://doi.org/10.2174/0115665232306205240419091414","url":null,"abstract":"Recent decades have seen advancements in the management and treatment of difficult-- to-treat diseases such as cancer. A special class of therapeutics called cell and gene therapy has been introduced in the past 10 years. Cell and gene therapy products have strengthened the treatment options for life-threatening diseases with unmet clinical needs and also provided the possibility of a potential cure for the disease in some of the patients. Cell and gene therapy products are gaining recognition, and the interest in clinical development of cell and gene therapy products is increasing. Moreover, as the class of cell and gene therapy products is relatively new, there is a limited regulatory experience in the development, and the developers of the cell and gene therapy products can often be puzzled with an array of questions on regulations. The current review intends to provide a basic understanding of regulatory guidelines from the FDA and EMA that are applicable to cell and gene therapy products. Essentials such as which office is responsible for the evaluation of applications, which regulatory class/pathway is appropriate for development, and what are the quality, nonclinical and clinical studies that are needed to support the application are discussed in the article. In addition, a summary of regulatory designations and the post-approval requirements, such as Risk Evaluation and Mitigation Strategies (REMS) and long-term follow- up, is included in the article. Developers (referred to as ‘sponsors’ in this article) of cell and gene therapies can use the respective guidance documents and other specific review articles cited in this review for detailed information on the topics.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"33 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells 非编码 RNA 对癌症细胞放疗敏感性和耐受性的作用
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-04-27 DOI: 10.2174/0115665232301727240422092311
Fatemeh Jalali-Zefrei, Seyed Mehdi Mousavi, Kourosh Delpasand, Mohammad Shourmij, Soghra Farzipour
: Radiotherapy (RT) is an integral part of treatment management in cancer patients. However, one of the limitations of this treatment method is the resistance of cancer cells to radiotherapy. These restrictions necessitate the introduction of modalities for the radiosensitization of cancer cells. It has been shown that Noncoding RNAs (ncRNAs), along with modifiers, can act as radiosensitivity and radioresistant regulators in a variety of cancers by affecting double strand break (DSB), wnt signaling, glycolysis, irradiation induced apoptosis, ferroptosis and cell autophagy. This review will provide an overview of the latest research on the roles and regulatory mechanisms of ncRNA after RT in in vitro and preclinical research.
:放射治疗(RT)是癌症患者治疗过程中不可或缺的一部分。然而,这种治疗方法的局限性之一是癌细胞对放疗的抗药性。由于这些限制,有必要引入对癌细胞进行放射增敏的方法。研究表明,非编码 RNA(ncRNA)和修饰因子可通过影响双链断裂(DSB)、wnt 信号转导、糖酵解、辐照诱导的细胞凋亡、铁凋亡和细胞自噬,在多种癌症中充当放射敏感性和抗放射调节因子。本综述将概述体外和临床前研究中有关 RT 后 ncRNA 作用和调控机制的最新研究。
{"title":"Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells","authors":"Fatemeh Jalali-Zefrei, Seyed Mehdi Mousavi, Kourosh Delpasand, Mohammad Shourmij, Soghra Farzipour","doi":"10.2174/0115665232301727240422092311","DOIUrl":"https://doi.org/10.2174/0115665232301727240422092311","url":null,"abstract":": Radiotherapy (RT) is an integral part of treatment management in cancer patients. However, one of the limitations of this treatment method is the resistance of cancer cells to radiotherapy. These restrictions necessitate the introduction of modalities for the radiosensitization of cancer cells. It has been shown that Noncoding RNAs (ncRNAs), along with modifiers, can act as radiosensitivity and radioresistant regulators in a variety of cancers by affecting double strand break (DSB), wnt signaling, glycolysis, irradiation induced apoptosis, ferroptosis and cell autophagy. This review will provide an overview of the latest research on the roles and regulatory mechanisms of ncRNA after RT in in vitro and preclinical research.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"20 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140810447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of Prime Editing Systems: Move Forward to the Treatment of Hereditary Diseases 基因编辑系统的演变:向治疗遗传性疾病迈进
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-04-16 DOI: 10.2174/0115665232295117240405070809
Olga V. Volodina, Anastasia R. Fabrichnikova, Arina A. Anuchina, Olesya S. Mishina, Alexander V. Lavrov, Svetlana A. Smirnikhina
: The development of gene therapy using genome editing tools recently became relevant. With the invention of programmable nucleases, it became possible to treat hereditary diseases due to introducing targeted double strand break in the genome followed by homology directed repair (HDR) or non-homologous end-joining (NHEJ) reparation. CRISPR-Cas9 is more efficient and easier to use in comparison with other programmable nucleases. To improve the efficiency and safety of this gene editing tool, various modifications CRISPR-Cas9 basis were created in recent years, such as prime editing – in this system, Cas9 nickase is fused with reverse transcriptase and guide RNA, which contains a desired correction. Prime editing demonstrates equal or higher correction efficiency as HDR-mediated editing and much less off-target effect due to inducing nick. There are several studies in which prime editing is used to correct mutations in which researchers reported little or no evidence of off-target effects. The system can also be used to functionally characterize disease variants. However, prime editing still has several limitations that could be further improved. The effectiveness of the method is not yet high enough to apply it in clinical trials. Delivery of prime editors is also a big challenge due to their size. In the present article, we observe the development of the platform, and discuss the candidate proteins for efficiency enhancing, main delivery methods and current applications of prime editing.
:利用基因组编辑工具进行基因治疗的发展近来变得十分重要。随着可编程核酸酶的发明,通过在基因组中引入靶向双链断裂,然后进行同源定向修复(HDR)或非同源末端连接(NHEJ)修复,治疗遗传性疾病成为可能。与其他可编程核酸酶相比,CRISPR-Cas9 更高效、更易用。为了提高这种基因编辑工具的效率和安全性,近年来出现了各种基于CRISPR-Cas9的改良方法,如质粒编辑--在这种系统中,Cas9缺口酶与反转录酶和含有所需校正的引导RNA融合。质粒编辑与 HDR 介导的编辑具有相同或更高的校正效率,而且由于诱导缺口而产生的脱靶效应要小得多。有几项研究使用质粒编辑来校正突变,研究人员报告称几乎没有证据表明存在脱靶效应。该系统还可用于确定疾病变异的功能特征。不过,质粒编辑仍有一些局限性,有待进一步改进。该方法的有效性还不足以将其应用于临床试验。由于质粒编辑器体积庞大,其输送也是一个巨大的挑战。在本文中,我们观察了该平台的发展,并讨论了提高效率的候选蛋白质、主要的传递方法和当前的素编辑应用。
{"title":"Evolution of Prime Editing Systems: Move Forward to the Treatment of Hereditary Diseases","authors":"Olga V. Volodina, Anastasia R. Fabrichnikova, Arina A. Anuchina, Olesya S. Mishina, Alexander V. Lavrov, Svetlana A. Smirnikhina","doi":"10.2174/0115665232295117240405070809","DOIUrl":"https://doi.org/10.2174/0115665232295117240405070809","url":null,"abstract":": The development of gene therapy using genome editing tools recently became relevant. With the invention of programmable nucleases, it became possible to treat hereditary diseases due to introducing targeted double strand break in the genome followed by homology directed repair (HDR) or non-homologous end-joining (NHEJ) reparation. CRISPR-Cas9 is more efficient and easier to use in comparison with other programmable nucleases. To improve the efficiency and safety of this gene editing tool, various modifications CRISPR-Cas9 basis were created in recent years, such as prime editing – in this system, Cas9 nickase is fused with reverse transcriptase and guide RNA, which contains a desired correction. Prime editing demonstrates equal or higher correction efficiency as HDR-mediated editing and much less off-target effect due to inducing nick. There are several studies in which prime editing is used to correct mutations in which researchers reported little or no evidence of off-target effects. The system can also be used to functionally characterize disease variants. However, prime editing still has several limitations that could be further improved. The effectiveness of the method is not yet high enough to apply it in clinical trials. Delivery of prime editors is also a big challenge due to their size. In the present article, we observe the development of the platform, and discuss the candidate proteins for efficiency enhancing, main delivery methods and current applications of prime editing.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"44 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140586457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Pembrolizumab单药或联合疗法对转移性三阴性乳腺癌患者的疗效和安全性:随机对照试验的系统回顾和元分析
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-03-12 DOI: 10.2174/0115665232283880240301035621
Mahmood Araghi, Farshad Gharebakhshi, Fatemeh Faramarzi, Alireza mafi, Tahoora Mousavi, Mina Alimohammadi, Hussein Soleimantabar
Background: Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC. Methods: To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models. Results: According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune-related adverse events of 22.7%. Conclusion: A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.
背景:转移性三阴性乳腺癌(mTNBC转移性三阴性乳腺癌(mTNBC)是侵袭性最强的乳腺癌,转移和复发的风险更大。已有研究对pembrolizumab的优缺点进行了深入分析,大量试验的早期数据表明,mTNBC患者的疗效显著。本荟萃分析比较了众多相关研究的数据,以评估pembrolizumab单药或联合疗法治疗mTNBC的安全性和有效性。研究方法为了确定符合条件的 RCT,我们使用电子数据库进行了全面的文献检索。利用 CMA 软件使用固定效应和随机效应模型进行异质性检验。结果根据我们的汇总数据,中位无进展生存期(PFS)为 2.66 个月,中位总生存期(OS)为 12.26 个月。此外,通过比较 PD-L1 阳性组和 PD-L1 阴性组的疗效指标,我们发现 PD-L1 的过度表达与 OS、PFS 和 ORR 之间存在相关性。与PD-L1阴性肿瘤患者相比,PD-L1阳性肿瘤患者的反应率更高,ORR为21.1%。一线免疫疗法的ORR高于≥二线免疫疗法。此外,pembrolizumab+联合治疗导致的免疫相关不良事件发生率为22.7%。结论mTNBC患者对pembrolizumab单药治疗有一定的反应。此外,PD-L1阳性、非肝/肺转移、联合治疗和一线免疫治疗可能预示着Pembrolizumab治疗的更好结果。Pembrolizumab与化疗联合使用可能对PD-L1阳性肿瘤患者更有利。
{"title":"Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","authors":"Mahmood Araghi, Farshad Gharebakhshi, Fatemeh Faramarzi, Alireza mafi, Tahoora Mousavi, Mina Alimohammadi, Hussein Soleimantabar","doi":"10.2174/0115665232283880240301035621","DOIUrl":"https://doi.org/10.2174/0115665232283880240301035621","url":null,"abstract":"Background: Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC. Methods: To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models. Results: According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune-related adverse events of 22.7%. Conclusion: A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"290 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140115293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Functions and Application Prospects of Hepatocyte Growth Factor in Reproduction 肝细胞生长因子在生殖领域的功能和应用前景
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-02-28 DOI: 10.2174/0115665232291010240221104445
Xin Mi, Caiyi Chen, Chen Feng, Yingying Qin, Zi-Jiang Chen, Yajuan Yang, Shidou Zhao
: Hepatocyte growth factor (HGF) is expressed in multiple systems and mediates a variety of biological activities, such as mitosis, motility, and morphogenesis. A growing number of studies have revealed the expression patterns and functions of HGF in ovarian and testicular physiology from the prenatal to the adult stage. HGF regulates folliculogenesis and steroidogenesis by modulating the functions of theca cells and granulosa cells in the ovary. It also mediates somatic cell proliferation and steroidogenesis, thereby affecting spermatogenesis in males. In addition to its physiological effects on the reproductive system, HGF has shown advantages in preclinical studies over recent years for the treatment of male and female infertility, particularly in women with premature ovarian insufficiency. This review aims to summarize the pleiotropic functions of HGF in the reproductive system and to provide prospects for its clinical application.
:肝细胞生长因子(HGF)在多个系统中表达,并介导多种生物活动,如有丝分裂、运动和形态发生。越来越多的研究揭示了肝细胞生长因子在卵巢和睾丸从出生前到成年阶段的生理过程中的表达模式和功能。HGF 通过调节卵巢中卵丘细胞和颗粒细胞的功能来调节卵泡生成和类固醇生成。它还能介导体细胞增殖和类固醇生成,从而影响男性的精子发生。除了对生殖系统的生理作用外,近年来,HGF 在治疗男性和女性不孕症,尤其是卵巢早衰妇女不孕症的临床前研究中也显示出其优势。本综述旨在总结 HGF 在生殖系统中的多种功能,并展望其临床应用前景。
{"title":"The Functions and Application Prospects of Hepatocyte Growth Factor in Reproduction","authors":"Xin Mi, Caiyi Chen, Chen Feng, Yingying Qin, Zi-Jiang Chen, Yajuan Yang, Shidou Zhao","doi":"10.2174/0115665232291010240221104445","DOIUrl":"https://doi.org/10.2174/0115665232291010240221104445","url":null,"abstract":": Hepatocyte growth factor (HGF) is expressed in multiple systems and mediates a variety of biological activities, such as mitosis, motility, and morphogenesis. A growing number of studies have revealed the expression patterns and functions of HGF in ovarian and testicular physiology from the prenatal to the adult stage. HGF regulates folliculogenesis and steroidogenesis by modulating the functions of theca cells and granulosa cells in the ovary. It also mediates somatic cell proliferation and steroidogenesis, thereby affecting spermatogenesis in males. In addition to its physiological effects on the reproductive system, HGF has shown advantages in preclinical studies over recent years for the treatment of male and female infertility, particularly in women with premature ovarian insufficiency. This review aims to summarize the pleiotropic functions of HGF in the reproductive system and to provide prospects for its clinical application.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"170 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140008252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Bovine Lactoferrin Treatment on Iron Homeostasis and Gene Expression Changes in Multiple Organ Dysfunctions During Wound Healing Process in Rats 牛乳铁蛋白处理对大鼠伤口愈合过程中铁稳态和多器官功能障碍基因表达变化的影响
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-02-22 DOI: 10.2174/0115665232279426240217174738
Ahmet Sarper Bozkurt, Şenay Görücü Yılmaz
Background:: Injury systemically disrupts the homeostatic balance and can cause organ failure. LF mediates both iron-dependent and iron-independent mechanisms, and the role of LF in regulating iron homeostasis is vital in terms of metabolism. Objectives:: In this study, we evaluated the organ-level effect and gene expression change of bLf in the cutaneous repair process. Materials and Methods:: An excisional full-thickness skin defect (FTSD) wound model was created in male Sprague Dawley rats (180-250 g) (n = 48) fed a high-fat diet (HFD) and the PHGPx, SLC7A11 and SLC40A1 genes and iron metabolism were evaluated. The animals were randomly divided into 6 groups: 1- Control, 2- bLf (200 mg/kg/day, oral), 3- FTSD (12 mm in diameter, dorsal), 4- HFD + bLf, 5- HFD + FTSD, 6- HFD + FTSD + bLf. Histologically, iron accumulation was demonstrated by Prussian blue staining in the liver, kidney, and intestinal tissues. Gene expression analysis was performed with qPCR. Results:: Histologically, iron accumulation was demonstrated by Prussian blue staining in the liver, kidney, and intestinal tissues. Prussian blue reactions were detected in the kidney. PHPGx and SLC7A11 genes in kidney and liver tissue were statistically significant (P < 0.05) except for the SLC40A1 gene (P > 0.05). Expression changes of the three genes were not statistically significant in analyses of rat intestinal tissue (P = 0.057). Conclusion:: In the organ-level ferroptotic damage mechanism triggered by wound formation. BLf controls the expression of three genes and manages iron deposition in these three tissues. In addition, it suppressed the increase in iron that would drive the cell to ferroptosis and anemia caused by inflammation, thereby eliminating iron deposition in the tissues.
背景损伤会破坏体内平衡,导致器官衰竭。LF 可介导铁依赖性和铁依赖性机制,LF 在调节铁平衡方面的作用对新陈代谢至关重要。研究目的本研究评估了 bLf 在皮肤修复过程中的器官效应和基因表达变化。材料与方法以饲喂高脂饮食(HFD)的雄性 Sprague Dawley 大鼠(180-250 g)(n = 48)为对象,建立切除性全厚度皮肤缺损(FTSD)伤口模型,并对 PHGPx、SLC7A11 和 SLC40A1 基因及铁代谢进行评估。动物被随机分为 6 组:1- 对照组,2- bLf(200 毫克/千克/天,口服)组,3- FTSD(直径 12 毫米,背侧)组,4- HFD + bLf 组,5- HFD + FTSD 组,6- HFD + FTSD + bLf 组。组织学上,肝脏、肾脏和肠道组织的普鲁士蓝染色显示了铁的积累。基因表达分析通过 qPCR 进行。结果组织学上,肝脏、肾脏和肠道组织的普鲁士蓝染色显示了铁的积累。肾脏中检测到普鲁士蓝反应。除 SLC40A1 基因(P> 0.05)外,肝肾组织中 PHPGx 和 SLC7A11 基因的表达均有统计学意义(P< 0.05)。在对大鼠肠道组织的分析中,这三个基因的表达变化无统计学意义(P = 0.057)。结论在由伤口形成引发的器官级铁变态损伤机制中。BLf 可控制三个基因的表达,并管理这三个组织中的铁沉积。此外,它还抑制了铁的增加,而铁的增加会促使细胞发生铁变态反应和炎症引起的贫血,从而消除组织中的铁沉积。
{"title":"Effect of Bovine Lactoferrin Treatment on Iron Homeostasis and Gene Expression Changes in Multiple Organ Dysfunctions During Wound Healing Process in Rats","authors":"Ahmet Sarper Bozkurt, Şenay Görücü Yılmaz","doi":"10.2174/0115665232279426240217174738","DOIUrl":"https://doi.org/10.2174/0115665232279426240217174738","url":null,"abstract":"Background:: Injury systemically disrupts the homeostatic balance and can cause organ failure. LF mediates both iron-dependent and iron-independent mechanisms, and the role of LF in regulating iron homeostasis is vital in terms of metabolism. Objectives:: In this study, we evaluated the organ-level effect and gene expression change of bLf in the cutaneous repair process. Materials and Methods:: An excisional full-thickness skin defect (FTSD) wound model was created in male Sprague Dawley rats (180-250 g) (n = 48) fed a high-fat diet (HFD) and the PHGPx, SLC7A11 and SLC40A1 genes and iron metabolism were evaluated. The animals were randomly divided into 6 groups: 1- Control, 2- bLf (200 mg/kg/day, oral), 3- FTSD (12 mm in diameter, dorsal), 4- HFD + bLf, 5- HFD + FTSD, 6- HFD + FTSD + bLf. Histologically, iron accumulation was demonstrated by Prussian blue staining in the liver, kidney, and intestinal tissues. Gene expression analysis was performed with qPCR. Results:: Histologically, iron accumulation was demonstrated by Prussian blue staining in the liver, kidney, and intestinal tissues. Prussian blue reactions were detected in the kidney. PHPGx and SLC7A11 genes in kidney and liver tissue were statistically significant (P &lt; 0.05) except for the SLC40A1 gene (P &gt; 0.05). Expression changes of the three genes were not statistically significant in analyses of rat intestinal tissue (P = 0.057). Conclusion:: In the organ-level ferroptotic damage mechanism triggered by wound formation. BLf controls the expression of three genes and manages iron deposition in these three tissues. In addition, it suppressed the increase in iron that would drive the cell to ferroptosis and anemia caused by inflammation, thereby eliminating iron deposition in the tissues.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"15 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139952682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biogenesis and Function of circRNAs in Pulmonary Fibrosis 肺纤维化中 circRNA 的生物生成和功能
IF 3.6 4区 医学 Q2 GENETICS & HEREDITY Pub Date : 2024-02-13 DOI: 10.2174/0115665232284076240207073542
Songzi Zhang, Wenjie Hu, Changjun Lv, Xiaodong Song
: Pulmonary fibrosis is a class of fibrosing interstitial lung diseases caused by many pathogenic factors inside and outside the lung, with unknown mechanisms and without effective treatment. Therefore, a comprehensive understanding of the molecular mechanism implicated in pulmonary fibrosis pathogenesis is urgently needed to develop new and effective measures. Although circRNAs have been widely acknowledged as new contributors to the occurrence and development of diseases, only a small number of circRNAs have been functionally characterized in pulmonary fibrosis. Here, we systematically review the biogenesis and functions of circRNAs and focus on how circRNAs participate in pulmonary fibrogenesis by influencing various cell fates. Meanwhile, we analyze the current exploration of circRNAs as a diagnostic biomarker, vaccine, and therapeutic target in pulmonary fibrosis and objectively discuss the challenges of circRNA-based therapy for pulmonary fibrosis. We hope that the review of the implication of circRNAs will provide new insights into the development circRNA-based approaches to treat pulmonary fibrosis.
:肺纤维化是一类由肺内外多种致病因素引起的纤维化间质性肺部疾病,其发病机制不明,且无有效治疗方法。因此,迫切需要全面了解肺纤维化发病的分子机制,以制定新的有效措施。尽管人们普遍认为循环RNA是导致疾病发生和发展的新因素,但只有少数循环RNA在肺纤维化中得到了功能表征。在此,我们系统地回顾了circRNAs的生物发生和功能,并重点研究了circRNAs如何通过影响各种细胞命运参与肺纤维化的发生。同时,我们分析了目前将circRNAs作为肺纤维化诊断生物标志物、疫苗和治疗靶点的探索,并客观地讨论了基于circRNA的肺纤维化治疗所面临的挑战。希望通过对circRNAs影响的综述,能为开发基于circRNA的肺纤维化治疗方法提供新的见解。
{"title":"Biogenesis and Function of circRNAs in Pulmonary Fibrosis","authors":"Songzi Zhang, Wenjie Hu, Changjun Lv, Xiaodong Song","doi":"10.2174/0115665232284076240207073542","DOIUrl":"https://doi.org/10.2174/0115665232284076240207073542","url":null,"abstract":": Pulmonary fibrosis is a class of fibrosing interstitial lung diseases caused by many pathogenic factors inside and outside the lung, with unknown mechanisms and without effective treatment. Therefore, a comprehensive understanding of the molecular mechanism implicated in pulmonary fibrosis pathogenesis is urgently needed to develop new and effective measures. Although circRNAs have been widely acknowledged as new contributors to the occurrence and development of diseases, only a small number of circRNAs have been functionally characterized in pulmonary fibrosis. Here, we systematically review the biogenesis and functions of circRNAs and focus on how circRNAs participate in pulmonary fibrogenesis by influencing various cell fates. Meanwhile, we analyze the current exploration of circRNAs as a diagnostic biomarker, vaccine, and therapeutic target in pulmonary fibrosis and objectively discuss the challenges of circRNA-based therapy for pulmonary fibrosis. We hope that the review of the implication of circRNAs will provide new insights into the development circRNA-based approaches to treat pulmonary fibrosis.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"82 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139770762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current gene therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1